Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Go back to Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial| RITE AID CORPORATION (NYSE: RAD) | Delayed: 0.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $8.30 | |||
| Open | $11.16 | 52 Week Low | $6.33 | |||
| Day High | $0.65 | P/E | 1.91 | |||
| Day Low | $0.65 | EPS | $0.34 | |||
| Volume | 63,391 | |||||
| (NASDAQ: RADX) | Delayed: 2.08 -0.08 (3.7%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.16 | 52 Week High | $ | |||
| Open | $2.05 | 52 Week Low | $ | |||
| Day High | $2.15 | P/E | N/A | |||
| Day Low | $2.05 | EPS | $ | |||
| Volume | 7,910 | |||||
